What Is 17β-hydroxysteroid dehydrogenases

Overview

17β-hydroxysteroid dehydrogenases (17β-HSDs) are a group of enzymes critical in the biosynthesis and metabolism of steroid hormones. These enzymes primarily interconvert less active ketosteroids into more potent hydroxysteroids, especially in sex hormones like testosterone and estradiol. Their role is pivotal in maintaining hormonal balance across various tissues.

Found in multiple organs including the liver, gonads, placenta, and adrenal glands, 17β-HSDs regulate local hormone concentrations. Because they control the activation or inactivation of steroids, they are key targets in treating hormone-dependent diseases such as breast and prostate cancers. Their tissue-specific expression patterns make them ideal for targeted therapies.

• At least 14 isoforms of 17β-HSD have been identified in humans, each encoded by a separate gene and exhibiting unique substrate preferences and tissue distribution.
• 17β-HSD1 is primarily expressed in the ovary and placenta and mainly catalyzes the reduction of estrone to estradiol, the most biologically active estrogen.
• 17β-HSD3 is localized in the testes and converts androstenedione to testosterone, a crucial step in male sexual development during fetal life.
• Deficiency in 17β-HSD3 leads to 46,XY disorders of sex development, with over 95% of affected individuals presenting with ambiguous genitalia at birth.
• Some isoforms, like 17β-HSD5 (AKR1C3), are upregulated in hormone-sensitive cancers, making them biomarkers and potential therapeutic targets.

How It Works

17β-HSDs function by catalyzing redox reactions on the C17 position of steroid molecules, either activating or deactivating them depending on the isoform and tissue context. These enzymes rely on cofactors such as NADH or NADPH and are influenced by pH, substrate concentration, and cellular environment.

• Reduction Reaction: 17β-HSD1 uses NADPH to reduce estrone (E1) into estradiol (E2), increasing estrogenic activity by up to 10-fold in breast tissue.
• Oxidation Reaction: 17β-HSD2 oxidizes estradiol back to estrone, acting as a protective mechanism in tissues like the endometrium to limit estrogen exposure.
• Substrate Specificity: Each isoform shows distinct preferences; for example, 17β-HSD5 metabolizes both androgens and progestins, contributing to multi-hormone regulation.
• Tissue Localization: 17β-HSD7 is highly expressed in the brain and adrenal glands, suggesting roles in neurosteroid metabolism and stress response regulation.
• Gene Regulation: The HSD17B genes are regulated by transcription factors such as SF-1 and LRH-1, which are active in steroidogenic tissues during development.
• Enzyme Kinetics: 17β-HSD1 has a Km of 0.2 μM for estrone, indicating high affinity and efficiency in estrogen activation.

Key Comparison

This table highlights the functional diversity among 17β-HSD isoforms. Their distinct roles underscore the complexity of steroid regulation and the importance of isoform-specific targeting in drug development.

Key Facts

Understanding the specific characteristics of each 17β-HSD isoform provides insight into their physiological and pathological roles. These enzymes are not only essential for normal development but also implicated in various endocrine disorders and cancers.

• 17β-HSD1 was first cloned in 1989, enabling targeted research into estrogen-dependent diseases and the development of inhibitors.
• Studies show that 17β-HSD2 expression decreases by 70% in endometrial cancer, leading to elevated local estradiol levels.
• Genetic mutations in HSD17B3 cause 17β-HSD3 deficiency, affecting approximately 1 in 147,000 male births worldwide.
• 17β-HSD5 is overexpressed in 80% of castration-resistant prostate cancers, contributing to intratumoral androgen synthesis.
• The HSD17B7 gene, located on chromosome 10q21, is essential for fetal development and cholesterol metabolism.
• Pharmacological inhibition of 17β-HSD1 has reached Phase II clinical trials for treating endometriosis and breast cancer.

Why It Matters

17β-hydroxysteroid dehydrogenases are central to endocrine health, influencing development, reproduction, and disease. Their role in fine-tuning hormone levels makes them critical in both normal physiology and pathological conditions.

• Targeted cancer therapies aim to inhibit specific 17β-HSD isoforms to reduce tumor growth in hormone-dependent cancers like breast and prostate cancer.
• Diagnostic biomarkers such as elevated 17β-HSD5 levels help identify aggressive forms of prostate cancer and guide treatment decisions.
• Developmental disorders linked to 17β-HSD deficiencies require early diagnosis and hormone replacement to support normal sexual development.
• Endocrine disruptors in the environment may interfere with 17β-HSD activity, potentially affecting fertility and increasing cancer risk.
• Personalized medicine approaches use isoform expression profiles to tailor hormone therapies, improving efficacy and reducing side effects.

As research advances, 17β-HSDs continue to emerge as vital players in endocrinology, offering new avenues for diagnosis, treatment, and prevention of hormone-related conditions.